Fig 8.tif (467.92 kB)
Locomotor studies of nuciferine.
figure
posted on 2016-03-10, 09:18 authored by Martilias S. Farrell, John D. McCorvy, Xi-Ping Huang, Daniel J. Urban, Kate L. White, Patrick M. Giguere, Allison K. Doak, Alison I. Bernstein, Kristen A. Stout, Su Mi Park, Ramona M. Rodriguiz, Bradley W. Gray, William S. Hyatt, Andrew P. Norwood, Kevin A. Webster, Brenda M. Gannon, Gary W. Miller, Joseph H. Porter, Brian K. Shoichet, William E. Fantegrossi, William C. Wetsel, Bryan L. Roth(a) Nuciferine suppresses the PCP-induced hyperlocomotor response. Data are presented as total distance travelled in 5-minute bins (left) and as cumulative distance travelled between minute 45 and minute 60 (right). N = 18 mice; ^p<0.05, compared to PCP group. (b) Nuciferine (3.0 mg/kg, 15 minute pretreatment) enhances the hyperlocomotor effect of amphetamine (3.0 mg/kg) administration. N = 14 mice; * < 0.001 compared to Amphetamine group. Data are presented as above.
History
Usage metrics
Categories
Keywords
D 4 receptorsdrug discrimination paradigms.ResultsNuciferine shares2A2B2CPCPHTdiscriminative stimulus effectsantipsychotic drug actionnuciferineagonistclozapine discriminative stimulus1ANelumbo nuciferaAlkaloid Nuciferine RationaleThesimilarity ensemble approachprofilePsychoactive Drug Screening Program
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC